CompanyProfileandconferences.com promote a new conference on "4th
Pharmacovigilance 2013" gives information about Latest developments in
pharmacovigilance, drug safety and risk management to ensure safer drugs to
market.
Conference on 4th Pharmacovigilance 2013 To be held on 12th to13th March 2013 at Hotel Marriott, London UK
CONFERENCE INTRODUCTION:-
It is estimated that the average spend on pharmacovigilance is 6% to 13% of a companies total R&D. From product development in clinical trials to post marketing surveillance, adverse drug reactions are monitored and safety signals investigated. The new legislation includes sweeping changes that leave industry with a lot of questions. If you want to file your product in Europe (MAA), what new PV regulatory processes do you need to put in place? Will the Pharmacovigilance System Master File be useful? And what is really meant by a Quality Management System?
The Conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the ke issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences.
4th Pharmacovigilance 2013 is the latest in Virtue Insight's series of successful pharmacovigilance events. Also it can help you control your product's lifecycle, your patient's trust, and your revenue. Hence, 4th Pharmacovigilance 2013 will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance Market development.
It gives me great pleasure in welcoming all of you to the Virtue Insight's I wish and pray that all our efforts
will be beneficial to our industries and to our country at large.
KEY THEMES DISCUSSED AT THIS CONFERENCE:-
Exploiting the latest technologies, methodologies and introducing pharmacy automations on work practices of Pharmacovigilance in EU, US and Asia
• Impact of the new European Pharmacovigilance legislation - Implementation and Beyond
• Keeping abreast of the changes impacting the drug safety industry to ensure the pharmacovigilance strategies are robust and geared to compliance
• Recent successful strategies and business models to bring out new medicines
• How will PV activities change with Clinical Trial Transformation Initiative?
• Discover approaches for collecting, integrating and analyzing all of the safety data generated from preclinical models
• Identifying essential antidote requirements and learn to implement best practices in drug safety and surveillance
• Exploiting the pharmacy automations and technologies for enhancement of medication safety
• Impact of technology – learn and explore
• Latest developments in pharmacovigilance, drug safety and risk management to ensure safer drugs to market
• Improving patient care and safety in relation to use of medicines and all medical and paramedical interventions
• Determining the steps and strategies for enhancing quality in healthcare
Conference on 4th Pharmacovigilance 2013 To be held on 12th to13th March 2013 at Hotel Marriott, London UK
CONFERENCE INTRODUCTION:-
It is estimated that the average spend on pharmacovigilance is 6% to 13% of a companies total R&D. From product development in clinical trials to post marketing surveillance, adverse drug reactions are monitored and safety signals investigated. The new legislation includes sweeping changes that leave industry with a lot of questions. If you want to file your product in Europe (MAA), what new PV regulatory processes do you need to put in place? Will the Pharmacovigilance System Master File be useful? And what is really meant by a Quality Management System?
The Conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the ke issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences.
4th Pharmacovigilance 2013 is the latest in Virtue Insight's series of successful pharmacovigilance events. Also it can help you control your product's lifecycle, your patient's trust, and your revenue. Hence, 4th Pharmacovigilance 2013 will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance Market development.
It gives me great pleasure in welcoming all of you to the Virtue Insight's I wish and pray that all our efforts
will be beneficial to our industries and to our country at large.
KEY THEMES DISCUSSED AT THIS CONFERENCE:-
Exploiting the latest technologies, methodologies and introducing pharmacy automations on work practices of Pharmacovigilance in EU, US and Asia
• Impact of the new European Pharmacovigilance legislation - Implementation and Beyond
• Keeping abreast of the changes impacting the drug safety industry to ensure the pharmacovigilance strategies are robust and geared to compliance
• Recent successful strategies and business models to bring out new medicines
• How will PV activities change with Clinical Trial Transformation Initiative?
• Discover approaches for collecting, integrating and analyzing all of the safety data generated from preclinical models
• Identifying essential antidote requirements and learn to implement best practices in drug safety and surveillance
• Exploiting the pharmacy automations and technologies for enhancement of medication safety
• Impact of technology – learn and explore
• Latest developments in pharmacovigilance, drug safety and risk management to ensure safer drugs to market
• Improving patient care and safety in relation to use of medicines and all medical and paramedical interventions
• Determining the steps and strategies for enhancing quality in healthcare
For more information kindly visit : 4th Pharmacovigilance 2013
Or
Contact us at :
Company Profiles And Conferences
Phone : + 91 22 27812707
Fax : + 91 22 27812290
E-mail : info@companyprofilesandconferences.com
Website : www.companyprofilesandconferences.com
Or
Contact us at :
Company Profiles And Conferences
Phone : + 91 22 27812707
Fax : + 91 22 27812290
E-mail : info@companyprofilesandconferences.com
Website : www.companyprofilesandconferences.com
No comments:
Post a Comment